Lung cancer (non-small-cell, second line) - gefitinib (terminated appraisal)
Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal)
Summary
NICE is unable to recommend the use in the NHS of gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer because no evidence submission was received from the manufacturer or sponsor of the technology.
Guidance documents
Implementing this guidance
Other information
About this guidance
Technology appraisals TA175
Issued: July 2009
How this guidance was produced